<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7066069\results\search\disease\results.xml">
  <result pre="terms. Abstract Chikungunya virus (CHIKV) is the causative pathogen of" exact="chikungunya" post="fever, a mosquito-borne viral disease causing highly debilitating arthralgia"/>
  <result pre="(CHIKV) is the causative pathogen of chikungunya fever, a mosquito-borne" exact="viral disease" post="causing highly debilitating arthralgia that can persist for months"/>
  <result pre="genome of live-attenuated vaccines and offer a novel immunization strategy." exact="chikungunya" post="vaccine liposome RNA live-attenuated Funding National Health and Medical"/>
  <result pre="equation-count: ref-count: page-count: word-count: Introduction Chikungunya fever is a mosquito-borne" exact="viral disease" post="caused by the chikungunya virus (CHIKV). CHIKV is a"/>
  <result pre="Chikungunya fever is a mosquito-borne viral disease caused by the" exact="chikungunya" post="virus (CHIKV). CHIKV is a positive-sense single-stranded RNA (+ssRNA)"/>
  <result pre="individuals infected with CHIKV develop disease (5, 6). Symptoms of" exact="chikungunya" post="disease are characterized by the acute onset of fever"/>
  <result pre="A high proportion of patients experience prolonged articular pain and" exact="arthritis" post="lasting several weeks to years (7). This chronic form"/>
  <result pre="with CHIKV infection include hepatitis, Guillain-Barré syndrome, myocarditis, retinitis, and" exact="nephritis" post="(8). Increases in mortality have been described in several"/>
  <result pre="salt adjuvanted with a glycolipid immunomodulator (18). Recent work with" exact="tuberculosis" post="and malaria antigens has shown that CAF01-delivered vaccines are"/>
  <result pre="with a glycolipid immunomodulator (18). Recent work with tuberculosis and" exact="malaria" post="antigens has shown that CAF01-delivered vaccines are able to"/>
  <result pre="trials in combination with four different peptide antigens including a" exact="tuberculosis" post="vaccine candidate and an HIV-1 peptide cocktail (21). Upon"/>
  <result pre="model of acute CHIKV disease recapitulates the arthritis, tenosynovitis, and" exact="myositis" post="associated with mononuclear cell infiltration seen in CHIKV-infected patients."/>
  <result pre="Hyg. (2010) 104:133–8. 10.1016/j.trstmh.2009.07.01419709705 2.RenaultPSoletJLSissokoDBalleydierELarrieuSFilleulLet al.. A major epidemic of" exact="chikungunya" post="virus infection on Reunion Island, France, 2005-2006. Am J"/>
  <result pre="for Europe. Eurosurveillance. (2014) 19:17–27. 10.2807/1560-7917.ES2014.19.13.2075924721539 5.QueyriauxBSimonFGrandadamMMichelRTolouHBoutinJP. Clinical burden of" exact="chikungunya" post="virus infection. Lancet Infect Dis. (2008) 8:2–3. 10.1016/S1473-3099(07)70294-318156079 6.SimonFJavelleEOliverMLeparc-GoffartIMarimoutouC."/>
  <result pre="Rep. (2011) 13:218–28. 10.1007/s11908-011-0180-121465340 7.EdingtonFVarjaoDMeloP. Incidence of articular pain and" exact="arthritis" post="after chikungunya fever in the Americas: a systematic review"/>
  <result pre="13:218–28. 10.1007/s11908-011-0180-121465340 7.EdingtonFVarjaoDMeloP. Incidence of articular pain and arthritis after" exact="chikungunya" post="fever in the Americas: a systematic review of the"/>
  <result pre="Joint Bone Spine. (2018) 85:669–78. 10.1016/j.jbspin.2018.03.01930053609 8.RajapakseSRodrigoCRajapakseA. Atypical manifestations of" exact="chikungunya" post="infection. Trans R Soc Trop Med Hyg. (2010) 104:89–96."/>
  <result pre="and Martinique, islands of the French West Indies, during the" exact="chikungunya" post="epidemic of 2014. Epidemiol Infect. (2018) 146:2059–65. 10.1017/S095026881800231530152293 10.StaplesJEBreimanRFPowersAM."/>
  <result pre="10.1017/S095026881800231530152293 10.StaplesJEBreimanRFPowersAM. Chikungunya fever: an epidemiological review of a re-emerging" exact="infectious disease." post="Clin Infect Dis. (2009) 49:942–8. 10.1086/60549619663604 11.de BritoCAATeixeiraMGIncreased number"/>
  <result pre="(2009) 49:942–8. 10.1086/60549619663604 11.de BritoCAATeixeiraMGIncreased number of deaths during a" exact="chikungunya" post="epidemic in Pernambuco, Brazil. Memorias do Instituto Oswaldo Cruz."/>
  <result pre="112:650–1. 10.1590/0074-0276017012428902292 12.TaylorALiuXZaidAGohLYHobson-PetersJHallRAet al.. Mutation of the N-terminal region of" exact="chikungunya" post="virus capsid protein: implications for vaccine design. Mbio. (2017)"/>
  <result pre="8:e01970–16. 10.1128/mBio.01970-1628223458 13.AbeyratneEFreitasJRZaidAMahalingamSTaylorA. Attenuation and stability of CHIKV-NoLS, a live-attenuated" exact="chikungunya" post="virus vaccine candidate. Vaccines. (2018) 7:2. 10.3390/vaccines701000230583514 14.RichnerJMHimansuSDowdKAButlerSLSalazarVFoxJMet al.."/>
  <result pre="liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M." exact="tuberculosis" post="(trehalose 6,6′-dibehenate) - A novel adjuvant inducing both strong"/>
  <result pre="streptococcus. Sci Rep. (2016) 6:39274. 10.1038/srep3927427976706 23.ChanYHTeoTHUttATanJJLAmrunSNAbu BakarFet al.. Mutating" exact="chikungunya" post="virus non-structural protein produces potent live-attenuated vaccine candidate. EMBO"/>
  <result pre="10.15252/emmm.20181009231015278 24.EdelmanRTacketCOWassermanSSBodisonSAPerryJGMangiaficoJA. Phase II safety and immunogenicity study of live" exact="chikungunya" post="virus vaccine TSI-GSD-218. Am J Trop Med Hyg. (2000)"/>
  <result pre="Hyg. (2000) 62:681–5. 10.4269/ajtmh.2000.62.68111304054 25.HallengardDLumFMKummererBMLullaALullaVGarcia-ArriazaJet al.. Prime-boost immunization strategies against" exact="chikungunya" post="virus. J Virol. (2014) 88:13333–43. 10.1128/JVI.01926-1425210177 26.PardiNWeissmanD. Nucleoside modified"/>
  <result pre="mRNA encoding a potently neutralizing human monoclonal antibody protects against" exact="chikungunya" post="infection. Sci Immunol. (2019) 4:eaaw6647. 10.1126/sciimmunol.aaw664731101672 28.RuddPARaphaelAPYamadaMNuferKLGardnerJLeTTTet al.. Effective"/>
  <result pre="4:eaaw6647. 10.1126/sciimmunol.aaw664731101672 28.RuddPARaphaelAPYamadaMNuferKLGardnerJLeTTTet al.. Effective cutaneous vaccination using an inactivated" exact="chikungunya" post="virus vaccine delivered by Foroderm. Vaccine. (2015) 33:5172–80. 10.1016/j.vaccine.2015.07.09926296498"/>
  <result pre="J Virol. (2014) 88:2858–66. 10.1128/JVI.03453-1324371047 30.LumFMCoudercTChiaBSOngRYHerZChowAet al.. Antibody-mediated enhancement aggravates" exact="chikungunya" post="virus infection and disease severity. Sci Rep. (2018) 8:1860."/>
 </snippets>
</snippetsTree>
